Literature DB >> 2961945

Effects of flutamide and aminoglutethimide on plasma 5 alpha-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate.

M Brochu1, A Bélanger, A Dupont, L Cusan, F Labrie.   

Abstract

Plasma levels of androstane-3 alpha, 17 beta-diol glucuronide (3 alpha-diol-G) and androsterone glucuronide (ADT-G) have been found to be effective markers of C-19 steroid metabolism in periphery in man. The present study has been performed in order to study in castrated patients the effect of antiandrogen administered alone or in combination with aminoglutethimide (AG) on the metabolism of adrenal C-19 steroid. Ten castrated patients with prostatic cancer received flutamide (FLU) alone for 2 months and, afterwards, the combined therapy of FLU and AG for 2 months. Antiandrogen treatment alone reduces the levels of dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone glucuronide (DHEA-G) and androstenedione (4-ene-dione) by 43, 34 and 38% (P less than or equal to 0.01) respectively while dehydroepiandrosterone (DHEA), androst-5-ene-3 beta,17 beta-diol (5-ene-diol) and androst-5-ene-3 beta,17 beta-diol-glucuronide (5-ene-diol-G) levels show a nonsignificant inhibition. In these patients, plasma 3 alpha-diol-G and ADT-G concentrations are nonsignificantly stimulated to 122 and 143%. Moreover, when patients were receiving the combined administration of FLU and AG, adrenal C-19 steroids were further inhibited while both 3 alpha-diol-G and ADT-G show a small but nonsignificant decrease. Our data indicate that the antiandrogen increases the formation and/or the metabolism of adrenal C-19 steroids into steroid glucuronides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961945     DOI: 10.1016/0022-4731(87)90388-8

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  7 in total

Review 1.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.

Authors:  R N Brogden; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 2.  A risk-benefit assessment of pharmacological therapies for hirsutism.

Authors:  E Carmina
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.

Authors:  R N Brogden; P Chrisp
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

4.  The use of flutamide in the management of hirsutism.

Authors:  M Marugo; D Bernasconi; M Meozzi; P Del Monte; V Zino; P Primarolo; B Badaracco
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

5.  The impact of antiandrogen 2-hydroxyflutamide on the expression of steroidogenic enzymes in cultured porcine ovarian follicles.

Authors:  Malgorzata Duda; Malgorzata Grzesiak; Malgorzata Knet; Katarzyna Knapczyk-Stwora; Zbigniew Tabarowski; Agata Michna; Maria Slomczynska
Journal:  Mol Biol Rep       Date:  2014-03-02       Impact factor: 2.316

6.  A Comprehensive Evaluation of Steroid Metabolism in Women with Intrahepatic Cholestasis of Pregnancy.

Authors:  Antonín Pařízek; Martin Hill; Michaela Dušková; Libor Vítek; Marta Velíková; Radmila Kancheva; Patrik Šimják; Michal Koucký; Zuzana Kokrdová; Karolína Adamcová; Andrej Černý; Zdeněk Hájek; Luboslav Stárka
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

7.  Altered Steroidome in Women with Gestational Diabetes Mellitus: Focus on Neuroactive and Immunomodulatory Steroids from the 24th Week of Pregnancy to Labor.

Authors:  Leona Ondřejíková; Antonín Pařízek; Patrik Šimják; Daniela Vejražková; Marta Velíková; Kateřina Anderlová; Michala Vosátková; Hana Krejčí; Michal Koucký; Radmila Kancheva; Michaela Dušková; Markéta Vaňková; Josef Bulant; Martin Hill
Journal:  Biomolecules       Date:  2021-11-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.